Avanza Fonder’s Compass Therapeutics CMPX Stock Holding History

Avanza Fonder’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,347	Closed	-$147K	–	492
2025 Q4	$147K	Buy	+27,347	New	+$126K	﹤0.01%	446

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Avanza Fonder's CMPX Position: Q1 2026 in Review

Avanza Fonder sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 27,347 shares — an estimated $147K sold.

Avanza Fonder first reported a position in CMPX in Q4 2025 and held it in 1 quarter. The position peaked at $147K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

Avanza Fonder reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
Avanza Fonder sold 27,347 Compass Therapeutics shares in Q1 2026, an estimated $147K.
Avanza Fonder first reported a position in Compass Therapeutics in Q4 2025 and held it in 1 quarter.
Avanza Fonder's Compass Therapeutics position peaked at $147K in Q4 2025.
201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.